These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Secondary osteoporosis. Bisphosphonates as a possible strategy for the prevention of bone destruction in rheumatoid arthritis].
    Author: Suzuki Y.
    Journal: Clin Calcium; 2007 Dec; 17(12):1909-13. PubMed ID: 18057668.
    Abstract:
    Recent studies demonstrated that osteoclastic bone resorption played an important role in joint destruction by rheumatoid synovium. Bisphosphnates inhibit osteoclastic bone resorption and have been widely used for the treatment of osteoporosis. Bisphosphonates, such as zolendronic acid (ZA) inhibited bone destruction in animal models of inflammatory arthritis, although the drug was not effective for the suppression of inflammation. In early RA patients, ZA was effective to prevent bone destruction in combination with methotrexate. Targeting osteoclasts with bisphosphonates is an effective strategy to maintain joint integrity when combined with anti-rheumatic therapy.
    [Abstract] [Full Text] [Related] [New Search]